Prostate Tissue BioBank

Last updated: October 24, 2024
Sponsor: Abramson Cancer Center at Penn Medicine
Overall Status: Active - Recruiting

Phase

N/A

Condition

Prostate Cancer

Treatment

N/A

Clinical Study ID

NCT06659614
UPCC 21823
IRB 854327
  • Ages > 18
  • Male

Study Summary

Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. We have shown that 5% of men diagnosed with prostate cancer localized to their prostate gland and up to 10-15% of patients with metastatic prostate cancer gland are carriers of an inherited gene mutation.

The Prostate Tissue BioBank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline DNA from pathogenic mutation carriers in addition to age-matched control samples. Our primary goal is to investigate prostate cancer development and treatment response in carriers of germline DNA repair mutations, as compared to non-carrier controls.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Carriers (Group 1):

  1. Confirmed pathogenic or likely pathogenic variant in a known prostate cancer riskgene.

  2. Patients undergoing prostate biopsies as a part of their prostate cancer screeningOR biopsy or prostatectomy due to a diagnosis of prostate cancer

Controls (Group 2):

  1. Patients undergoing prostate biopsies as a part of their prostate cancer screeningOR biopsy or prostatectomy due to a diagnosis of prostate cancer

Exclusion

Exclusion Criteria:

  • N/A

Study Design

Total Participants: 200
Study Start date:
January 01, 2024
Estimated Completion Date:
January 31, 2034

Connect with a study center

  • University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.